These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2225948)

  • 21. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the quality of life in children with cystic fibrosis.
    Kotwicki RJ; Condra L; Vermeulen L; Wolf T; Douglas J; Farrell PM
    WMJ; 2001; 100(5):50-4. PubMed ID: 11579801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temocillin in cystic fibrosis: a retrospective pilot study.
    Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
    J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home treatment of pulmonary infection in cystic fibrosis.
    Kuzemko JA
    Chest; 1988 Aug; 94(2 Suppl):162S-166S. PubMed ID: 3396439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhaled liposomal amikacin.
    Waters V; Ratjen F
    Expert Rev Respir Med; 2014 Aug; 8(4):401-9. PubMed ID: 24882271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
    Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
    Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis: intravenous treatment at home.
    Catchpole A
    Nurs Times; 1989 Mar 22-28; 85(12):40-2. PubMed ID: 2717454
    [No Abstract]   [Full Text] [Related]  

  • 34. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Lau WK; Young LS; Osher AB; Dooley RR
    Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
    Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
    Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Flume PA; Morris N; Konstan MW
    J Cyst Fibros; 2016 Nov; 15(6):783-790. PubMed ID: 27139161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhaled antibiotic therapy in cystic fibrosis].
    Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis.
    Rayment JH; Stanojevic S; Davis SD; Retsch-Bogart G; Ratjen F
    Thorax; 2018 May; 73(5):451-458. PubMed ID: 29449440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment.
    Abou-Hatab K; Nixon LS; O'Mahony MS; Newsway V; Patel S; Shale DJ; Woodhouse KW
    Eur J Clin Pharmacol; 1999 Feb; 54(12):937-41. PubMed ID: 10192754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.